Nuage Therapeutics Appoints New CEO and Chair to Drive Precision Therapies
Company - People | Apr 07, 2025 | Sofinnova Partners
Nuage Therapeutics, a biotech company in Barcelona, has announced key leadership changes, naming Stuart Hughes as the new CEO and Vanessa Malier as Chair of the Board. Hughes, with extensive R&D and leadership experience from his previous role at Pathios Therapeutics, will lead Nuage as it focuses on advancing its proprietary technology in drug discovery for intrinsically disordered proteins, aiming to unlock new therapeutic pathways particularly in cancer treatments. Malier, a seasoned board member and advisor within the biotech and venture capital sectors, will support this push. The transition is supported by significant investors including Sofinnova Partners and Asabys Partners, who believe strongly in Nuage's potential for transformative impact within the precision medicine landscape.
Sectors
- Biotechnology
- Pharmaceuticals
- Private Equity
Geography
- Spain – Nuage Therapeutics is based in the biotech and pharma hub of Barcelona, Spain.
- United Kingdom – The new CEO, Stuart Hughes, has previous ties with Pathios Therapeutics, indicating a cross-border element in leadership experience.
Industry
- Biotechnology – The article discusses changes within a biotech company, Nuage Therapeutics, which is focused on precision therapies and drug discovery involving complex protein targets.
- Pharmaceuticals – Nuage Therapeutics' work in developing small molecule drug discovery techniques places it within the pharmaceuticals sector, particularly in oncology.
- Private Equity – Sofinnova Partners and other investors are involved, highlighting the role of private equity in funding and guiding the company's development strategy.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Nuage Therapeutics S.L. | Target Company | Company | A biotech company focused on creating transformational precision therapies, particularly in oncology. |
| Sofinnova Partners | Investor | Company | A principal investor in Nuage Therapeutics and a significant player in the transition and strategic growth direction of the company. |
| Stuard Hughes | CEO | Person | Newly appointed CEO of Nuage Therapeutics with extensive experience in drug discovery and biotech leadership. |
| Vanessa Malier | Chair of the Board | Person | New Chair of the Board at Nuage Therapeutics and a seasoned expert in biotech, venture capital, and private equity firms. |
| Asabys Partners | Investor | Company | Co-founder and supporter of Nuage Therapeutics, involved in its strategic growth. |
| Innvierte (CDTI) | Investor | Company | An investment program of the CDTI, supporting Nuage Therapeutics. |